GlassScriptPhysician profile
Diego Loaiza
NPI 1033526413
$4,787.44
in general payments reported to CMS, 2019-2025
33 companies · $846 in 2025
The $846 reported for 2025 was more than what 82% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,661 · 2022: $500 · 2023: $1,094 · 2024: $687 · 2025: $846.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,510 · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,509.58 |
| Education | $116.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $768.08 | 2021-2024 | |
| Novo Nordisk INC | $747.18 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $506.35 | 2021-2025 | Jardiance, Tradjenta |
| Lilly USA, LLC | $342.83 | 2021-2025 | Mounjaro, Zepbound |
| Exact Sciences Corporation | $295.96 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Gilead Sciences, INC. | $251.19 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $251.00 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $200.07 | 2022-2025 | Xifaxan, Trulance |
| Astellas Pharma US INC | $185.15 | 2023-2024 | Veozah |
| Glaxosmithkline, LLC. | $171.95 | 2021-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Mannkind Corporation | $124.98 | 2021 | |
| Amarin Pharma, INC. | $109.89 | 2021 | |
| Medtronic, INC. | $105.75 | 2022-2025 | Endurant Iis |
| Arbor Pharmaceuticals, INC. | $105.59 | 2021-2022 | |
| Amgen INC. | $76.70 | 2021-2025 | Repatha, Otezla, Prolia |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $65.44 | 2021-2023 | |
| Ironwood Pharmaceuticals, INC | $63.63 | 2023-2024 | Linzess |
| Pfizer INC. | $58.49 | 2022-2025 | |
| Abbott Laboratories | $50.29 | 2023 | Freestyle Libre |
| Sunovion Pharmaceuticals INC. | $47.59 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $26.90 | 2022 | |
| Medela LLC | $25.85 | 2024 | Invia Motion Endure |
| Lemaitre Vascular, INC. | $25.20 | 2025 | Artegraft Vascular Graft |
| Philips North America LLC | $23.20 | 2024 | (Ck7) Extended Holter |
| Organogenesis INC. | $22.50 | 2025 | Apligraf |
| Abiomed | $22.27 | 2024 | Impella |
| W. L. Gore & Associates, INC. | $18.60 | 2023 | Gore Synecor Biomaterial |
| Biohaven Pharmaceuticals, INC. | $18.16 | 2021 | |
| Currax Pharmaceuticals LLC | $17.22 | 2025 | Contrave |
| Madrigal Pharmaceuticals | $16.71 | 2025 | Rezdiffra |
| Davol INC. | $15.04 | 2022 | |
| Genentech USA, INC. | $14.87 | 2022 | |
| Alexion Pharmaceuticals, INC. | $12.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diego Loaiza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.